Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adriamycin + cyclophosphamide + lomustine + methotrexate
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a four-drug combination chemotherapy regimen known as MACC, consisting of doxorubicin hydrochloride (Adriamycin), cyclophosphamide, lomustine (CCNU), and methotrexate. The regimen has been primarily studied in advanced lung cancers such as bronchogenic carcinoma and non-small cell lung cancer (NSCLC). Each component acts via a distinct mechanism to inhibit cancer cell proliferation: - Doxorubicin (Adriamycin) is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II. - Cyclophosphamide is an alkylating agent that crosslinks DNA strands. - Lomustine is a nitrosourea alkylating agent causing DNA damage. - Methotrexate inhibits dihydrofolate reductase, blocking folic acid metabolism required for DNA synthesis. The combination aims to maximize antitumor activity by targeting different pathways involved in cell division. Clinical studies have shown moderate response rates with manageable toxicity profiles in advanced lung cancer patients[1][2][4].
- Other names
- methotrexate + doxorubicin + cyclophosphamide + lomustineMACC regimenmethotrexate/adriamycin/cyclophosphamide/lomustine
02
Targets
TOP2A (DNA topoisomerase II)DNADHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on adriamycin + cyclophosphamide + lomustine + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adriamycin + cyclophosphamide + lomustine + methotrexate.